Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator. We evaluated the effects of adjunctive treatment with brexpiprazole on sleep disturbances in
Highlights • Many patients with MDD experience symptoms that impair functioning and productivity. • Brexpiprazole+ADT was studied in young patients
Abstract Background: Approximately 50% of patients with major depressive disorder do not respond adequately to their antidepressant treatment, underscoring the
Highlights • Brexpiprazole is an adjunctive therapy for treatment of MDD. • Anxiety symptoms are prevalent in MDD and associated
Abstract Objective: To summarize efficacy data from two phase 2 and two phase 3 short-term, multicenter, randomized, double-blind, placebo-controlled studies
Abstract Background Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult‐to‐treat patient. Brexpiprazole is a serotonin–dopamine activity
Abstract Brexpiprazole is a new therapeutic agent that was recently approved for the treatment of schizophrenia and for the adjunctive
Abstract Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin,
